Statins may protect against NASH by inhibiting small GTPases. GTPases have diverse functions such as signal transduction, modulate protein synthesis, cell differentiation processes, or intracellular vesicle transport (27). In this line, a work developed by Schierwagen et al. (28) showed that treatment with simvastatin reduced liver inflammation and fibrosis in mice with NAFLD through inhibition of mice sarcoma protein. This work suggests that statins can change intracellular signaling. This mechanism may be responsible for the prospective liver effects in NAFLD/NASH.

PPARs are receptors that bind fatty acids and regulate inflammatory and metabolic pathways. Specifically, PPAR α acts mainly in the hepatocyte modulating lipid transport, β-oxidation and gluconeogenesis genes (29). This PPARs receptor became an attractive target to treat NAFLD/NASH and clinical trials are ongoing to evaluate the effect of PPAR agonists in these diseases (21). Thus, the mitochondria and peroxisome have an important role in the degradation of fatty acids and in steatohepatitis by the accumulation of cholesterol: specifically, it has been suggested that mitochondrial and peroxisomal activity can be increased by statins, thus, a study conducted on mice (30) after the consumption of standard chow or a diet with a reduced content in choline and methionine without or with different statins improved hepatic fatty acid oxidation via PPARα and its target genes. Moreover, in this study, steatosis, inflammation, and fibrosis improved with the use of statins. Interestingly, these findings were not associated with the intensity of statins (atorvastatin, fluvastatin, rosuvastatin, pravastatin, and simvastatin). In summary, these findings are relevant: they suggest that statins treatment reduce hepatic steatohepatitis.

PON 1 is an antioxidant enzyme from the liver and is related to a reduction in inflammation and antiatherogenic effects. The reduction of PON1 is a marker of lipid peroxidation that is improved by the use of statins (31). A trial conducted by Samy et al. (32) evaluated the use of statins in patients with NAFLD. 25 participants received 40 mg of atorvastatin daily for a period of 8 months and 25 received a placebo. The investigators evaluated, among others, liver ultrasonography, liver tests, lipids, and serum PON1 activity. After intervention, participants that received therapy with atorvastatin improved serum PON1 activity. KCs with crown-like structures and cholesterol are involved in inflammation, lipotoxicity, and fibrosis (33). In this context, a study in animal models (mice) investigator evaluated the effect of different interventions (34) including one group with ezetimibe, one group with atorvastatin, one group with atorvastatin plus ezetimibe, and one control group. Interestingly, animals that received atorvastatin and ezetimibe resolved cholesterol crystals, crown-like structures, and reduced fibrosis. In contrast, atorvastatin or ezetimibe alone developed a mild effect on these outcomes. This study provided evidence showing that the use of lipid-lowering drugs (including statins) reduces cholesterol crystals and modulate KC crown-like structures reducing NASH.

Hepatic stellate cells can be activated via paracrine of the hepatocyte and this activation results in fibrogenesis. This activation may be suppressed by statins treatment. Specifically, a study conducted using fluvastatin (35) in animal models showed that this treatment reduced profibrogenic pathways, showing the potential role of fluvastatin as an antifibrotic agent that could be used in NASH. Similar findings were demonstrated by simvastatin with in vivo and in vitro studies (1).

Liver endothelial cell function with reduced NO and stellate cells activation develop fibrosis. This could be modulated by statins. A study conducted in rats treated with simvastatin or atorvastatin (36) showed that statins reduced sinusoidal endothelial dysfunction, exerting the vasoprotective effects of these drugs.

Moreover, statins have anti-inflammatory and anti-fibrogenic effects. This was evaluated in a study that was developed to test the effect of rosuvastatin over different proinflammatory and profibrogenic factors (37). The rosuvastatin group showed a decrease in proinflammatory cytokines, including IL-6, TNF-α, IL-1β, and other angiogenic and profibrogenic factors. In this line, a trial with atorvastatin, vitamin E, and dietary intervention reduced the expression of fibrotic genes (38). All these findings support that statins could be protective against hepatic inflammation associated with NASH.

To sum up, statins improved liver endothelial cells dysfunction, receded activation of hepatic stellate cells, and exerted anti-fibrogenic effects.

The etiology of NASH/NAFLD is influenced by inflammation and oxidative stress. Statins by their pleiotropic effects might improve liver histology. As previously mentioned, animal models showed how statins reduce the progression of fibrosis by antioxidant and antioxidant effects (1, 39).

Small uncontrolled investigations in humans used ultrasonography and tomography to assess the effects of statins on hepatic steatosis, and the majority found that they improved this condition. In this sense, it is important to highlight two studies: a randomized trial with atorvastatin in which this drug was more effective than fenofibrate in reducing liver echogenicity (40) and a randomized trial with atorvastatin (10–20 mg daily), where atorvastatin was shown to be as effective as pitavastatin in reducing steatosis (41). If we analyze data on the effect of statins on liver histology, the data are limited but despite this, the use of statins may be justified as an adjunct therapy to treat other conditions associated with NASH/NAFLD (prediabetes/type 2 diabetes) (42, 43). Some retrospective studies report improvement in steatosis without change in inflammation or fibrosis in patients treated with statins and interestingly, progressions in fibrosis in those that did not receive statins (44). In summary, we can conclude that most of the retrospective studies show how statins could reduce hepatic steatosis with improvement inflammation (45–47). The main limitation of these studies is the small number of patients included that may explain the different responses between participants.

It is well established that elevations in serum aminotransferases are usual in patients that receive statins but in contrast (48), hepatic toxicity is not. In fact, the rate of acute liver failure in patients that are taking statins is very close to the general population (49). However, cases have been described of both autoimmune hepatitis associated with statin treatment (50) (Fluvastatin, atorvastatin, and rosuvastatin, among others) and acute liver failure requiring liver transplantation (0.01% of the causes of liver transplantation) (51). Another key point that may explain the alterations in liver function tests is due to the pharmacological interactions of statins rather than the toxic effect of these drugs (52).

Data from clinical trials such as the West of Scotland Coronary Prevention Study (WOSCOPS) (53), the Long-term Intervention with Pravastatin in Ischemic (LIPID) (54) study, and the Cholesterol And Recurrent Events (CARE) (55) suggest that long-term treatment with statins is tolerated without an excess of serious liver adverse events. On the other hand, meta-analyses have been developed to evaluate the effect of statins on liver function tests. One of them (56) analyzed almost 50,000 patients and showed that the use of statins (low or intermediate doses) was not associated with an alteration of liver enzymes. On the other hand, another study showed how comparatively high-dose statins increase the risk of transaminase elevation compared to low doses, especially in the case of hydrophilic statins (57).

Finally, it is important to highlight that the Statin Liver Safety Task Force established some years ago (58) the safety of statin treatment in patients with compensated cirrhosis, NASH, and NAFLD. In contrast, acute liver failure as long as decompensated cirrhosis contraindicate the use of statins.

We have previously described in the first section of this manuscript many in vitro/in vivo studies evaluating the impact of statins in NASH through various mechanisms including their influence on pro-inflammatory factors, hepatic cell activation, sinusoidal endothelial cells, PON1, PPARα, and GTPases modulation.

There are no randomized controlled trials that evaluate the role of statins on NASH. We could only find data from post hoc analyses of prospective studies showing a beneficial effect of statins on NASH (Table 1).

In a subanalysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) trial, which included coronary heart disease patients, the use of atorvastatin in patients with NASH/NAFLD improved liver enzymes and reduced cardiovascular events in those without alteration in liver tests after 3 years (59, 61).

The Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Study evaluated 1,123 participants with metabolic syndrome without diabetes or cardiovascular disease (60, 62). Participants were randomized into two groups: one with an LDL-C target under 130 mg/dl and the other with a target under 100 mg/dl. In the post hoc analysis liver enzymes and ultrasonography improved during the study.

Other relevant findings are those from a subanalysis from the Incremental Decrease in End Points Through Aggressive Lipid-Lowering (IDEAL) trial, which included >8,500 patients with established cardiovascular disease (60). Specifically, data from the post hoc analysis show that 1,081 have elevated ALT levels, probably due to NASH/ NAFLD. Participants with moderately elevated aminotransferase levels and received atorvastatin 80 mg daily normalized aminotransferase levels in contrast with those who received simvastatin 20–40 mg daily.

Other small trials, described in the previous section “Effects of Statins on Liver Histology” have been developed. These trials suggest the “biopsy-proven” effect of statins on NASH (40, 41, 44–47).

To our knowledge there is only one trial, with 70 participants (NCT04679376) (Table 1), to evaluate the safety and efficacy of statin therapy (atorvastatin 40 mg daily) for the treatment of NASH and hepatic fibrosis. This trial is active but not recruiting yet.

Dyslipidemia is a condition that is associated with NASH/NAFLD (42). Statins are the cornerstone of the treatment of hyperlipidemia. Although all statins seem to be effective to reduce cholesterol in patients with NASH, atorvastatin has a favorable profile to reduce the incidence of cardiovascular events in these patients. In the previous section we analyzed data from trials and effectiveness to treat NASH, but there is one important effect of these drugs in the participants involved in these trials: a reduction of CVD (Table 1). In the GREACE study, the subgroup of patients with NASH/ NAFLD that received statins had reduced CVD events, compared to those who had normal liver tests, and moreover, the investigators observed a reduction of CVD events compared with those with NAFLD without statins (59, 61). In the IDEAL study patients with a high dose of atorvastatin reduced the major CVD events (coronary and cerebrovascular events) compared to participants that received simvastatin (60). On the other hand, in the ATTEMPT study (62), the number of events were too low to establish a conclusion.

The latest ASL-EASD-EASO Clinical Practice Guidelines (63) support that the assessment of CVD risk must be developed in patients with NAFLD, and that they should receive treatment with statins if needed. Moreover, in the American Gastroenterological Association update for the treatment of Dyslipidemia in Common Liver Diseases (64), the author suggests that although NASH is not considered a traditional risk factor for the development of cardiovascular disease, it is commonly associated with hyperlipidemia, and statins are safe and well-tolerated in NASH patients to reduce CVD risk.